Komori
KYORIN Pharmaceutical (4569) · InitiativeCited as achieved

Business Development through the Transfer of All Shares in Doctor Program

First written in FY2017-Q3. 4 of 6 entries say "Cited as achieved", first in FY2018-Q1. Latest entry: FY2018.

6entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017-Q3Cited as achievedFY2018-Q1 – FY20182017: 420172018: 22018
Same theme, other companies
Removal from the Scope of Consolidation Through the Transfer of Shares in a SubsidiaryA theme 314 companies write about · 44 as a headwind · 223 as a tailwind

24 other companies' latest entry also says "Cited as achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 156 companies compared. The sentences above are computed from all 156.Comparing 200 of the theme's 397 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2018Cited as achievedAnnual report

    「As all shares of Dr.Program Co., Ltd. were transferred to Taisho Pharmaceutical Co., Ltd. effective 1 April 2017, sales of skincare products declined.」

    The completed transfer of all shares of Dr.Program and the resulting decline in skincare sales are cited as achievements.
  2. FY2018-Q3Cited as achievedAnnual report

    「Meanwhile, because all shares of Doctor Program Co., Ltd. were transferred to Taisho Pharmaceutical Co., Ltd. effective 1 April 2017, sales of skincare products declined.」

    The completed transfer of all shares of Dr.Program and the resulting decline in skincare sales are cited as achievements.
  3. FY2018-Q2Cited as achievedAnnual report

    「As all shares of Dr.Program Co., Ltd. were transferred to Taisho Pharmaceutical Co., Ltd. effective 1 April 2017, sales of skincare products declined.」

    The completed transfer of all shares and the resulting decline in skincare sales are cited as achievements.
  4. FY2018-Q1Cited as achievedAnnual report

    「As all shares of Dr.Program Co., Ltd. were transferred to Taisho Pharmaceutical Co., Ltd. effective 1 April 2017, sales of skincare products declined.」

    The transfer of all shares of Dr.Program was completed, resulting in lower skincare product sales, which was recorded as an achievement related to a change in business activities.
  5. FY2017AchievedAnnual report

    「With respect to Doctor Program Co., Ltd., which primarily handles skincare products, we decided to transfer all of its shares to Taisho Pharmaceutical Co., Ltd. This decision was based on our determination that developing the business under a company with strengths in the business-to-consumer sector would contribute more to the growth of its business. All shares were transferred on 1 April 2017.」

    The planned transfer of all shares of Doctor Program was executed on 1 April 2017.
  6. FY2017-Q3First statedAnnual report

    「We decided to transfer all shares in Doctor Program Co., Ltd., which primarily handles skincare products, to Taisho Pharmaceutical Co., Ltd. This decision was based on the view that continuing the business under a company with strength in B2C operations would contribute more to its development. The transfer was scheduled for 1 April 2017.」

    The Group decided to transfer all shares in Doctor Program to Taisho Pharmaceutical, with 1 April 2017 set as the scheduled closing date.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Business Development through the Transfer of All Shares in Doctor Program | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori